GHRH analog · long-acting

Tesamorelin

$65 10 mg · per vial
1
For research use only. Not for human consumption.
Route
Subcutaneous
Documentation
On request
Shipping
Discreet
Handling
Inspected on arrival

Long-acting GHRH analog studied primarily for its role in visceral fat regulation and body composition research. FDA-approved (as Egrifta) for HIV-associated lipodystrophy.

Watch
Deep research

Mechanism, common research protocols, evidence review, and cited primary literature for Tesamorelin live on the full guide.

Read the guide →